To further clarify the advantages of TACE combined with lenvatinib and tislelizumab in the treatment of HCC, subgroup analyses of patients based on tumor number, maximum tumor diameter, presence of PVTT, AFP level, and Child-Pugh classification were conducted. The gene discussed is AFP; the disease is neoplasm.